Outcome of Board Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Shree Ganesh Remedies Limited approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025. Revenue from operations stood at ₹2,466.79 lakhs, almost flat compared to ₹2,477.99 lakhs in Q1 FY25. However, profit after tax (standalone) declined sharply by about 26% to ₹344.94 lakhs from ₹465.39 lakhs in the same quarter last year. Profit before tax dropped to ₹459.80 lakhs from ₹633.49 lakhs. A key concern is the sharp jump in finance costs to ₹94.01 lakhs from ₹31.55 lakhs YoY, nearly tripling. The auditor, Chaudhary Shah & Associates LLP, issued an unmodified (clean) review report on both standalone and consolidated results.
Marginal revenue stability is offset by notable pressure on profitability, driven largely by sharply higher finance costs. Investors should watch for signs of debt-related stress, as the ~26% PAT decline and near-tripling of interest expenses suggest rising financial leverage or higher interest rates on borrowings.